Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Celyad OncologyLTS:0QFK -1.78%22 EV-to-EBITDA is 10.41 as of Aug. 22, 2026. GuruFocus rates LTS:0QFK with a GF Score™ of 22/100 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 406 Biotechnology companies, Celyad Oncology ranks better than 57.64% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Celyad Oncology's enterprise value is €11.43 Mil.
Celyad Oncology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €1.10 Mil. Therefore, Celyad Oncology's EV-to-EBITDA for today is 10.41.
The historical rank and industry rank for Celyad Oncology's EV-to-EBITDA or its related term are showing as below:
LTS:0QFK'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -18.28 Med: -1.35 Max: 10.41
Current: 10.41
During the past 13 years, the highest EV-to-EBITDA of Celyad Oncology was 10.41. The lowest was -18.28. And the median was -1.35.
LTS:0QFK's EV-to-EBITDA is ranked better than 57.64% of 406
companies
in the Biotechnology industry
Industry Median: 14.4
vs LTS:0QFK: 10.41
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Celyad Oncology's PE Ratio (TTM) for today is calculated as:
Celyad Oncology's share price for today is €0.276.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Celyad Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.018.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Celyad Oncology's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0QFK vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Celyad Oncology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celyad Oncology EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Celyad Oncology's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Celyad Oncology's EV-to-EBITDA falls into.
Celyad Oncology's current Enterprise Value is €11.43 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Celyad Oncology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €1.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celyad Oncology (LTS:0QFK) has a EV-to-EBITDA of 10.41 as of Aug. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Celyad Oncology. According to the industry distribution chart, Celyad Oncology ranks #172 out of 406 companies in the Biotechnology industry, placing it in the top 42.4%.
Is Celyad Oncology's EV-to-EBITDA too high?
Celyad Oncology's current EV-to-EBITDA is 10.41. The Biotechnology industry median EV-to-EBITDA is 14.40. Celyad Oncology's value of 10.41 is 27.7% below this industry median. Based on the distribution chart, Celyad Oncology ranks #172 out of 406 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Celyad Oncology has a GF Score™ of 22/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Celyad Oncology's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Celyad Oncology ranks #172 out of 406 companies for EV-to-EBITDA. This puts Celyad Oncology in the upper half of its industry. The industry median EV-to-EBITDA is 14.40. Celyad Oncology's value of 10.41 is 27.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 14.40, based on 406 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celyad Oncology's current EV-to-EBITDA of 10.41 is 27.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Celyad Oncology. For the Biotechnology industry, the median EV-to-EBITDA is 14.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celyad Oncology's current EV-to-EBITDA is 10.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celyad Oncology stock overvalued right now?
Based on GuruFocus' analysis, Celyad Oncology (LTS:0QFK) is currently considered Possible Value Trap. The current EV-to-EBITDA is 10.41 and 27.7% below the Biotechnology industry median of 14.40. Celyad Oncology's overall GF Score™ is 22/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Celyad Oncology (LTS:0QFK), the current EV-to-EBITDA is 10.41 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
22GF Score
Get the complete analysis for LTS:0QFK
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0QFK has been successfully added to your 
